Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL
Identifieur interne : 000A18 ( Main/Exploration ); précédent : 000A17; suivant : 000A19Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL
Auteurs : Paul M. Barr [États-Unis] ; Jennifer R. Brown [États-Unis] ; Peter Hillmen [Royaume-Uni] ; Susan O'Brien [États-Unis] ; Jacqueline C. Barrientos [États-Unis] ; Nishitha M. Reddy [États-Unis] ; Steven Coutre [États-Unis] ; Stephen P. Mulligan [Australie] ; Ulrich Jaeger [Autriche] ; Richard R. Furman [États-Unis] ; Florence Cymbalista [France] ; Marco Montillo [Italie] ; Claire Dearden [Royaume-Uni] ; Tadeusz Robak [Pologne] ; Carol Moreno [Espagne] ; John M. Pagel [États-Unis] ; Jan A. Burger [États-Unis] ; Samuel Suzuki [États-Unis] ; Juthamas Sukbuntherng [États-Unis] ; George Cole [États-Unis] ; Danelle F. James [États-Unis] ; John C. Byrd [États-Unis]Source :
- Blood [ 0006-4971 ] ; 2017.
Descripteurs français
- KwdFr :
- Antinéoplasiques (administration et posologie), Antinéoplasiques (usage thérapeutique), Femelle, Humains, Inhibiteurs de protéines kinases (administration et posologie), Inhibiteurs de protéines kinases (usage thérapeutique), Leucémie chronique lymphocytaire à cellules B (génétique), Leucémie chronique lymphocytaire à cellules B (traitement médicamenteux), Mutation, Mâle, Observance thérapeutique, Protein-tyrosine kinases (antagonistes et inhibiteurs), Protéine p53 suppresseur de tumeur (génétique), Pyrazoles (administration et posologie), Pyrazoles (usage thérapeutique), Pyrimidines (administration et posologie), Pyrimidines (usage thérapeutique), Relation dose-effet des médicaments, Survie sans rechute.
- MESH :
- administration et posologie : Antinéoplasiques, Inhibiteurs de protéines kinases, Pyrazoles, Pyrimidines.
- antagonistes et inhibiteurs : Protein-tyrosine kinases.
- génétique : Leucémie chronique lymphocytaire à cellules B, Protéine p53 suppresseur de tumeur.
- traitement médicamenteux : Leucémie chronique lymphocytaire à cellules B.
- usage thérapeutique : Antinéoplasiques, Inhibiteurs de protéines kinases, Pyrazoles, Pyrimidines.
- Femelle, Humains, Mutation, Mâle, Observance thérapeutique, Relation dose-effet des médicaments, Survie sans rechute.
English descriptors
- KwdEn :
- Antineoplastic Agents (administration & dosage), Antineoplastic Agents (therapeutic use), Disease-Free Survival, Dose-Response Relationship, Drug, Female, Humans, Leukemia, Lymphocytic, Chronic, B-Cell (drug therapy), Leukemia, Lymphocytic, Chronic, B-Cell (genetics), Male, Mutation, Patient Compliance, Protein Kinase Inhibitors (administration & dosage), Protein Kinase Inhibitors (therapeutic use), Protein-Tyrosine Kinases (antagonists & inhibitors), Pyrazoles (administration & dosage), Pyrazoles (therapeutic use), Pyrimidines (administration & dosage), Pyrimidines (therapeutic use), Tumor Suppressor Protein p53 (genetics).
- MESH :
- chemical , administration & dosage : Antineoplastic Agents, Protein Kinase Inhibitors, Pyrazoles, Pyrimidines.
- chemical , antagonists & inhibitors : Protein-Tyrosine Kinases.
- chemical , genetics : Tumor Suppressor Protein p53.
- chemical , therapeutic use : Antineoplastic Agents, Protein Kinase Inhibitors, Pyrazoles, Pyrimidines.
- drug therapy : Leukemia, Lymphocytic, Chronic, B-Cell.
- genetics : Leukemia, Lymphocytic, Chronic, B-Cell.
- Disease-Free Survival, Dose-Response Relationship, Drug, Female, Humans, Male, Mutation, Patient Compliance.
Abstract
Higher ibrutinib DI is associated with improved PFS, independent of del17p or Ibrutinib hold for >1 week, often needed to manage adverse events, is associated with increased PFS events.
Url:
DOI: 10.1182/blood-2016-12-737346
PubMed: 28373262
PubMed Central: 5437732
Affiliations:
- Australie, Autriche, Espagne, France, Italie, Pologne, Royaume-Uni, États-Unis
- Angleterre, Californie, Catalogne, Grand Londres, Lombardie, Massachusetts, Ohio, Tennessee, Texas, Vienne (Autriche), Washington (État), État de New York, Île-de-France
- Barcelone, Londres, Milan, Paris, Vienne (Autriche)
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 001810
- to stream Pmc, to step Curation: 001670
- to stream Pmc, to step Checkpoint: 000253
- to stream PubMed, to step Corpus: 000C29
- to stream PubMed, to step Curation: 000C26
- to stream PubMed, to step Checkpoint: 000C26
- to stream Ncbi, to step Merge: 004574
- to stream Ncbi, to step Curation: 004574
- to stream Ncbi, to step Checkpoint: 004574
- to stream Main, to step Merge: 000A13
- to stream Main, to step Curation: 000A18
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL</title><author><name sortKey="Barr, Paul M" sort="Barr, Paul M" uniqKey="Barr P" first="Paul M." last="Barr">Paul M. Barr</name><affiliation wicri:level="2"><nlm:aff id="aff1">Wilmot Cancer Institute, University of Rochester, Rochester, NY;</nlm:aff><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Wilmot Cancer Institute, University of Rochester, Rochester</wicri:cityArea></affiliation></author><author><name sortKey="Brown, Jennifer R" sort="Brown, Jennifer R" uniqKey="Brown J" first="Jennifer R." last="Brown">Jennifer R. Brown</name><affiliation wicri:level="2"><nlm:aff id="aff2">Dana-Farber Cancer Institute, Boston, MA;</nlm:aff><country xml:lang="fr">États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Dana-Farber Cancer Institute, Boston</wicri:cityArea></affiliation></author><author><name sortKey="Hillmen, Peter" sort="Hillmen, Peter" uniqKey="Hillmen P" first="Peter" last="Hillmen">Peter Hillmen</name><affiliation wicri:level="1"><nlm:aff id="aff3">The Leeds Teaching Hospitals, St. James Institute of Oncology, Leeds, United Kingdom;</nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>The Leeds Teaching Hospitals, St. James Institute of Oncology, Leeds</wicri:regionArea><wicri:noRegion>Leeds</wicri:noRegion></affiliation></author><author><name sortKey="O Brien, Susan" sort="O Brien, Susan" uniqKey="O Brien S" first="Susan" last="O'Brien">Susan O'Brien</name><affiliation wicri:level="2"><nlm:aff id="aff4">Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX;</nlm:aff><country xml:lang="fr">États-Unis</country><placeName><region type="state">Texas</region></placeName><wicri:cityArea>Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston</wicri:cityArea></affiliation></author><author><name sortKey="Barrientos, Jacqueline C" sort="Barrientos, Jacqueline C" uniqKey="Barrientos J" first="Jacqueline C." last="Barrientos">Jacqueline C. Barrientos</name><affiliation wicri:level="2"><nlm:aff id="aff5">Hofstra Northwell School of Medicine, Hempstead, NY;</nlm:aff><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Hofstra Northwell School of Medicine, Hempstead</wicri:cityArea></affiliation></author><author><name sortKey="Reddy, Nishitha M" sort="Reddy, Nishitha M" uniqKey="Reddy N" first="Nishitha M." last="Reddy">Nishitha M. Reddy</name><affiliation wicri:level="2"><nlm:aff id="aff6">Vanderbilt-Ingram Cancer Center, Nashville, TN;</nlm:aff><country xml:lang="fr">États-Unis</country><placeName><region type="state">Tennessee</region></placeName><wicri:cityArea>Vanderbilt-Ingram Cancer Center, Nashville</wicri:cityArea></affiliation></author><author><name sortKey="Coutre, Steven" sort="Coutre, Steven" uniqKey="Coutre S" first="Steven" last="Coutre">Steven Coutre</name><affiliation wicri:level="2"><nlm:aff id="aff7">Stanford Cancer Center, Stanford University School of Medicine, Stanford, CA;</nlm:aff><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Stanford Cancer Center, Stanford University School of Medicine, Stanford</wicri:cityArea></affiliation></author><author><name sortKey="Mulligan, Stephen P" sort="Mulligan, Stephen P" uniqKey="Mulligan S" first="Stephen P." last="Mulligan">Stephen P. Mulligan</name><affiliation wicri:level="1"><nlm:aff id="aff8">Royal North Shore Hospital, Sydney, NSW, Australia;</nlm:aff><country xml:lang="fr">Australie</country><wicri:regionArea>Royal North Shore Hospital, Sydney, NSW</wicri:regionArea><wicri:noRegion>NSW</wicri:noRegion></affiliation></author><author><name sortKey="Jaeger, Ulrich" sort="Jaeger, Ulrich" uniqKey="Jaeger U" first="Ulrich" last="Jaeger">Ulrich Jaeger</name><affiliation wicri:level="3"><nlm:aff id="aff9">Division of Hematology, Department of Medicine I, Medical University of Vienna, Vienna, Austria;</nlm:aff><country xml:lang="fr">Autriche</country><wicri:regionArea>Division of Hematology, Department of Medicine I, Medical University of Vienna, Vienna</wicri:regionArea><placeName><settlement type="city">Vienne (Autriche)</settlement><region nuts="2" type="province">Vienne (Autriche)</region></placeName></affiliation></author><author><name sortKey="Furman, Richard R" sort="Furman, Richard R" uniqKey="Furman R" first="Richard R." last="Furman">Richard R. Furman</name><affiliation wicri:level="2"><nlm:aff id="aff10">Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY;</nlm:aff><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Weill Cornell Medical College, New York Presbyterian Hospital, New York</wicri:cityArea></affiliation></author><author><name sortKey="Cymbalista, Florence" sort="Cymbalista, Florence" uniqKey="Cymbalista F" first="Florence" last="Cymbalista">Florence Cymbalista</name><affiliation wicri:level="3"><nlm:aff id="aff11">Hôpital Avicenne, Paris, France;</nlm:aff><country xml:lang="fr">France</country><wicri:regionArea>Hôpital Avicenne, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Montillo, Marco" sort="Montillo, Marco" uniqKey="Montillo M" first="Marco" last="Montillo">Marco Montillo</name><affiliation wicri:level="3"><nlm:aff id="aff12">Niguarda Ca’ Granda Hospital, Milan, Italy;</nlm:aff><country xml:lang="fr">Italie</country><wicri:regionArea>Niguarda Ca’ Granda Hospital, Milan</wicri:regionArea><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Dearden, Claire" sort="Dearden, Claire" uniqKey="Dearden C" first="Claire" last="Dearden">Claire Dearden</name><affiliation wicri:level="3"><nlm:aff id="aff13">Royal Marsden Hospital, London, United Kingdom;</nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Royal Marsden Hospital, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Robak, Tadeusz" sort="Robak, Tadeusz" uniqKey="Robak T" first="Tadeusz" last="Robak">Tadeusz Robak</name><affiliation wicri:level="1"><nlm:aff id="aff14">Department of Hematology, Medical University of Lodz, Lodz, Poland;</nlm:aff><country xml:lang="fr">Pologne</country><wicri:regionArea>Department of Hematology, Medical University of Lodz, Lodz</wicri:regionArea><wicri:noRegion>Lodz</wicri:noRegion></affiliation></author><author><name sortKey="Moreno, Carol" sort="Moreno, Carol" uniqKey="Moreno C" first="Carol" last="Moreno">Carol Moreno</name><affiliation wicri:level="3"><nlm:aff id="aff15">Hospital de la Santa Creu Sant Pau, Barcelona, Spain;</nlm:aff><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital de la Santa Creu Sant Pau, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Pagel, John M" sort="Pagel, John M" uniqKey="Pagel J" first="John M." last="Pagel">John M. Pagel</name><affiliation wicri:level="2"><nlm:aff id="aff16">Swedish Cancer Institute, Seattle, WA;</nlm:aff><country xml:lang="fr">États-Unis</country><placeName><region type="state">Washington (État)</region></placeName><wicri:cityArea>Swedish Cancer Institute, Seattle</wicri:cityArea></affiliation></author><author><name sortKey="Burger, Jan A" sort="Burger, Jan A" uniqKey="Burger J" first="Jan A." last="Burger">Jan A. Burger</name><affiliation wicri:level="2"><nlm:aff id="aff4">Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX;</nlm:aff><country xml:lang="fr">États-Unis</country><placeName><region type="state">Texas</region></placeName><wicri:cityArea>Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston</wicri:cityArea></affiliation></author><author><name sortKey="Suzuki, Samuel" sort="Suzuki, Samuel" uniqKey="Suzuki S" first="Samuel" last="Suzuki">Samuel Suzuki</name><affiliation wicri:level="2"><nlm:aff id="aff17">Pharmacyclics LLC, AbbVie, Sunnyvale, CA;</nlm:aff><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Pharmacyclics LLC, AbbVie, Sunnyvale</wicri:cityArea></affiliation></author><author><name sortKey="Sukbuntherng, Juthamas" sort="Sukbuntherng, Juthamas" uniqKey="Sukbuntherng J" first="Juthamas" last="Sukbuntherng">Juthamas Sukbuntherng</name><affiliation wicri:level="2"><nlm:aff id="aff17">Pharmacyclics LLC, AbbVie, Sunnyvale, CA;</nlm:aff><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Pharmacyclics LLC, AbbVie, Sunnyvale</wicri:cityArea></affiliation></author><author><name sortKey="Cole, George" sort="Cole, George" uniqKey="Cole G" first="George" last="Cole">George Cole</name><affiliation wicri:level="2"><nlm:aff id="aff17">Pharmacyclics LLC, AbbVie, Sunnyvale, CA;</nlm:aff><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Pharmacyclics LLC, AbbVie, Sunnyvale</wicri:cityArea></affiliation></author><author><name sortKey="James, Danelle F" sort="James, Danelle F" uniqKey="James D" first="Danelle F." last="James">Danelle F. James</name><affiliation wicri:level="2"><nlm:aff id="aff17">Pharmacyclics LLC, AbbVie, Sunnyvale, CA;</nlm:aff><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Pharmacyclics LLC, AbbVie, Sunnyvale</wicri:cityArea></affiliation></author><author><name sortKey="Byrd, John C" sort="Byrd, John C" uniqKey="Byrd J" first="John C." last="Byrd">John C. Byrd</name><affiliation wicri:level="2"><nlm:aff id="aff18">The Ohio State University Medical Center, The Ohio State University, Columbus, OH</nlm:aff><country xml:lang="fr">États-Unis</country><placeName><region type="state">Ohio</region></placeName><wicri:cityArea>The Ohio State University Medical Center, The Ohio State University, Columbus</wicri:cityArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">28373262</idno><idno type="pmc">5437732</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5437732</idno><idno type="RBID">PMC:5437732</idno><idno type="doi">10.1182/blood-2016-12-737346</idno><date when="2017">2017</date><idno type="wicri:Area/Pmc/Corpus">001810</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001810</idno><idno type="wicri:Area/Pmc/Curation">001670</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">001670</idno><idno type="wicri:Area/Pmc/Checkpoint">000253</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000253</idno><idno type="wicri:source">PubMed</idno><idno type="wicri:Area/PubMed/Corpus">000C29</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000C29</idno><idno type="wicri:Area/PubMed/Curation">000C26</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000C26</idno><idno type="wicri:Area/PubMed/Checkpoint">000C26</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000C26</idno><idno type="wicri:Area/Ncbi/Merge">004574</idno><idno type="wicri:Area/Ncbi/Curation">004574</idno><idno type="wicri:Area/Ncbi/Checkpoint">004574</idno><idno type="wicri:doubleKey">0006-4971:2017:Barr P:impact:of:ibrutinib</idno><idno type="wicri:Area/Main/Merge">000A13</idno><idno type="wicri:Area/Main/Curation">000A18</idno><idno type="wicri:Area/Main/Exploration">000A18</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL</title><author><name sortKey="Barr, Paul M" sort="Barr, Paul M" uniqKey="Barr P" first="Paul M." last="Barr">Paul M. Barr</name><affiliation wicri:level="2"><nlm:aff id="aff1">Wilmot Cancer Institute, University of Rochester, Rochester, NY;</nlm:aff><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Wilmot Cancer Institute, University of Rochester, Rochester</wicri:cityArea></affiliation></author><author><name sortKey="Brown, Jennifer R" sort="Brown, Jennifer R" uniqKey="Brown J" first="Jennifer R." last="Brown">Jennifer R. Brown</name><affiliation wicri:level="2"><nlm:aff id="aff2">Dana-Farber Cancer Institute, Boston, MA;</nlm:aff><country xml:lang="fr">États-Unis</country><placeName><region type="state">Massachusetts</region></placeName><wicri:cityArea>Dana-Farber Cancer Institute, Boston</wicri:cityArea></affiliation></author><author><name sortKey="Hillmen, Peter" sort="Hillmen, Peter" uniqKey="Hillmen P" first="Peter" last="Hillmen">Peter Hillmen</name><affiliation wicri:level="1"><nlm:aff id="aff3">The Leeds Teaching Hospitals, St. James Institute of Oncology, Leeds, United Kingdom;</nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>The Leeds Teaching Hospitals, St. James Institute of Oncology, Leeds</wicri:regionArea><wicri:noRegion>Leeds</wicri:noRegion></affiliation></author><author><name sortKey="O Brien, Susan" sort="O Brien, Susan" uniqKey="O Brien S" first="Susan" last="O'Brien">Susan O'Brien</name><affiliation wicri:level="2"><nlm:aff id="aff4">Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX;</nlm:aff><country xml:lang="fr">États-Unis</country><placeName><region type="state">Texas</region></placeName><wicri:cityArea>Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston</wicri:cityArea></affiliation></author><author><name sortKey="Barrientos, Jacqueline C" sort="Barrientos, Jacqueline C" uniqKey="Barrientos J" first="Jacqueline C." last="Barrientos">Jacqueline C. Barrientos</name><affiliation wicri:level="2"><nlm:aff id="aff5">Hofstra Northwell School of Medicine, Hempstead, NY;</nlm:aff><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Hofstra Northwell School of Medicine, Hempstead</wicri:cityArea></affiliation></author><author><name sortKey="Reddy, Nishitha M" sort="Reddy, Nishitha M" uniqKey="Reddy N" first="Nishitha M." last="Reddy">Nishitha M. Reddy</name><affiliation wicri:level="2"><nlm:aff id="aff6">Vanderbilt-Ingram Cancer Center, Nashville, TN;</nlm:aff><country xml:lang="fr">États-Unis</country><placeName><region type="state">Tennessee</region></placeName><wicri:cityArea>Vanderbilt-Ingram Cancer Center, Nashville</wicri:cityArea></affiliation></author><author><name sortKey="Coutre, Steven" sort="Coutre, Steven" uniqKey="Coutre S" first="Steven" last="Coutre">Steven Coutre</name><affiliation wicri:level="2"><nlm:aff id="aff7">Stanford Cancer Center, Stanford University School of Medicine, Stanford, CA;</nlm:aff><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Stanford Cancer Center, Stanford University School of Medicine, Stanford</wicri:cityArea></affiliation></author><author><name sortKey="Mulligan, Stephen P" sort="Mulligan, Stephen P" uniqKey="Mulligan S" first="Stephen P." last="Mulligan">Stephen P. Mulligan</name><affiliation wicri:level="1"><nlm:aff id="aff8">Royal North Shore Hospital, Sydney, NSW, Australia;</nlm:aff><country xml:lang="fr">Australie</country><wicri:regionArea>Royal North Shore Hospital, Sydney, NSW</wicri:regionArea><wicri:noRegion>NSW</wicri:noRegion></affiliation></author><author><name sortKey="Jaeger, Ulrich" sort="Jaeger, Ulrich" uniqKey="Jaeger U" first="Ulrich" last="Jaeger">Ulrich Jaeger</name><affiliation wicri:level="3"><nlm:aff id="aff9">Division of Hematology, Department of Medicine I, Medical University of Vienna, Vienna, Austria;</nlm:aff><country xml:lang="fr">Autriche</country><wicri:regionArea>Division of Hematology, Department of Medicine I, Medical University of Vienna, Vienna</wicri:regionArea><placeName><settlement type="city">Vienne (Autriche)</settlement><region nuts="2" type="province">Vienne (Autriche)</region></placeName></affiliation></author><author><name sortKey="Furman, Richard R" sort="Furman, Richard R" uniqKey="Furman R" first="Richard R." last="Furman">Richard R. Furman</name><affiliation wicri:level="2"><nlm:aff id="aff10">Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY;</nlm:aff><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Weill Cornell Medical College, New York Presbyterian Hospital, New York</wicri:cityArea></affiliation></author><author><name sortKey="Cymbalista, Florence" sort="Cymbalista, Florence" uniqKey="Cymbalista F" first="Florence" last="Cymbalista">Florence Cymbalista</name><affiliation wicri:level="3"><nlm:aff id="aff11">Hôpital Avicenne, Paris, France;</nlm:aff><country xml:lang="fr">France</country><wicri:regionArea>Hôpital Avicenne, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Montillo, Marco" sort="Montillo, Marco" uniqKey="Montillo M" first="Marco" last="Montillo">Marco Montillo</name><affiliation wicri:level="3"><nlm:aff id="aff12">Niguarda Ca’ Granda Hospital, Milan, Italy;</nlm:aff><country xml:lang="fr">Italie</country><wicri:regionArea>Niguarda Ca’ Granda Hospital, Milan</wicri:regionArea><placeName><settlement type="city">Milan</settlement><region nuts="2">Lombardie</region></placeName></affiliation></author><author><name sortKey="Dearden, Claire" sort="Dearden, Claire" uniqKey="Dearden C" first="Claire" last="Dearden">Claire Dearden</name><affiliation wicri:level="3"><nlm:aff id="aff13">Royal Marsden Hospital, London, United Kingdom;</nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Royal Marsden Hospital, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Robak, Tadeusz" sort="Robak, Tadeusz" uniqKey="Robak T" first="Tadeusz" last="Robak">Tadeusz Robak</name><affiliation wicri:level="1"><nlm:aff id="aff14">Department of Hematology, Medical University of Lodz, Lodz, Poland;</nlm:aff><country xml:lang="fr">Pologne</country><wicri:regionArea>Department of Hematology, Medical University of Lodz, Lodz</wicri:regionArea><wicri:noRegion>Lodz</wicri:noRegion></affiliation></author><author><name sortKey="Moreno, Carol" sort="Moreno, Carol" uniqKey="Moreno C" first="Carol" last="Moreno">Carol Moreno</name><affiliation wicri:level="3"><nlm:aff id="aff15">Hospital de la Santa Creu Sant Pau, Barcelona, Spain;</nlm:aff><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital de la Santa Creu Sant Pau, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Pagel, John M" sort="Pagel, John M" uniqKey="Pagel J" first="John M." last="Pagel">John M. Pagel</name><affiliation wicri:level="2"><nlm:aff id="aff16">Swedish Cancer Institute, Seattle, WA;</nlm:aff><country xml:lang="fr">États-Unis</country><placeName><region type="state">Washington (État)</region></placeName><wicri:cityArea>Swedish Cancer Institute, Seattle</wicri:cityArea></affiliation></author><author><name sortKey="Burger, Jan A" sort="Burger, Jan A" uniqKey="Burger J" first="Jan A." last="Burger">Jan A. Burger</name><affiliation wicri:level="2"><nlm:aff id="aff4">Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX;</nlm:aff><country xml:lang="fr">États-Unis</country><placeName><region type="state">Texas</region></placeName><wicri:cityArea>Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston</wicri:cityArea></affiliation></author><author><name sortKey="Suzuki, Samuel" sort="Suzuki, Samuel" uniqKey="Suzuki S" first="Samuel" last="Suzuki">Samuel Suzuki</name><affiliation wicri:level="2"><nlm:aff id="aff17">Pharmacyclics LLC, AbbVie, Sunnyvale, CA;</nlm:aff><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Pharmacyclics LLC, AbbVie, Sunnyvale</wicri:cityArea></affiliation></author><author><name sortKey="Sukbuntherng, Juthamas" sort="Sukbuntherng, Juthamas" uniqKey="Sukbuntherng J" first="Juthamas" last="Sukbuntherng">Juthamas Sukbuntherng</name><affiliation wicri:level="2"><nlm:aff id="aff17">Pharmacyclics LLC, AbbVie, Sunnyvale, CA;</nlm:aff><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Pharmacyclics LLC, AbbVie, Sunnyvale</wicri:cityArea></affiliation></author><author><name sortKey="Cole, George" sort="Cole, George" uniqKey="Cole G" first="George" last="Cole">George Cole</name><affiliation wicri:level="2"><nlm:aff id="aff17">Pharmacyclics LLC, AbbVie, Sunnyvale, CA;</nlm:aff><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Pharmacyclics LLC, AbbVie, Sunnyvale</wicri:cityArea></affiliation></author><author><name sortKey="James, Danelle F" sort="James, Danelle F" uniqKey="James D" first="Danelle F." last="James">Danelle F. James</name><affiliation wicri:level="2"><nlm:aff id="aff17">Pharmacyclics LLC, AbbVie, Sunnyvale, CA;</nlm:aff><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Pharmacyclics LLC, AbbVie, Sunnyvale</wicri:cityArea></affiliation></author><author><name sortKey="Byrd, John C" sort="Byrd, John C" uniqKey="Byrd J" first="John C." last="Byrd">John C. Byrd</name><affiliation wicri:level="2"><nlm:aff id="aff18">The Ohio State University Medical Center, The Ohio State University, Columbus, OH</nlm:aff><country xml:lang="fr">États-Unis</country><placeName><region type="state">Ohio</region></placeName><wicri:cityArea>The Ohio State University Medical Center, The Ohio State University, Columbus</wicri:cityArea></affiliation></author></analytic><series><title level="j">Blood</title><idno type="ISSN">0006-4971</idno><idno type="eISSN">1528-0020</idno><imprint><date when="2017">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antineoplastic Agents (administration & dosage)</term><term>Antineoplastic Agents (therapeutic use)</term><term>Disease-Free Survival</term><term>Dose-Response Relationship, Drug</term><term>Female</term><term>Humans</term><term>Leukemia, Lymphocytic, Chronic, B-Cell (drug therapy)</term><term>Leukemia, Lymphocytic, Chronic, B-Cell (genetics)</term><term>Male</term><term>Mutation</term><term>Patient Compliance</term><term>Protein Kinase Inhibitors (administration & dosage)</term><term>Protein Kinase Inhibitors (therapeutic use)</term><term>Protein-Tyrosine Kinases (antagonists & inhibitors)</term><term>Pyrazoles (administration & dosage)</term><term>Pyrazoles (therapeutic use)</term><term>Pyrimidines (administration & dosage)</term><term>Pyrimidines (therapeutic use)</term><term>Tumor Suppressor Protein p53 (genetics)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antinéoplasiques (administration et posologie)</term><term>Antinéoplasiques (usage thérapeutique)</term><term>Femelle</term><term>Humains</term><term>Inhibiteurs de protéines kinases (administration et posologie)</term><term>Inhibiteurs de protéines kinases (usage thérapeutique)</term><term>Leucémie chronique lymphocytaire à cellules B (génétique)</term><term>Leucémie chronique lymphocytaire à cellules B (traitement médicamenteux)</term><term>Mutation</term><term>Mâle</term><term>Observance thérapeutique</term><term>Protein-tyrosine kinases (antagonistes et inhibiteurs)</term><term>Protéine p53 suppresseur de tumeur (génétique)</term><term>Pyrazoles (administration et posologie)</term><term>Pyrazoles (usage thérapeutique)</term><term>Pyrimidines (administration et posologie)</term><term>Pyrimidines (usage thérapeutique)</term><term>Relation dose-effet des médicaments</term><term>Survie sans rechute</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antineoplastic Agents</term><term>Protein Kinase Inhibitors</term><term>Pyrazoles</term><term>Pyrimidines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Protein-Tyrosine Kinases</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Tumor Suppressor Protein p53</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Agents</term><term>Protein Kinase Inhibitors</term><term>Pyrazoles</term><term>Pyrimidines</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Antinéoplasiques</term><term>Inhibiteurs de protéines kinases</term><term>Pyrazoles</term><term>Pyrimidines</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Protein-tyrosine kinases</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Leukemia, Lymphocytic, Chronic, B-Cell</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Leukemia, Lymphocytic, Chronic, B-Cell</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Leucémie chronique lymphocytaire à cellules B</term><term>Protéine p53 suppresseur de tumeur</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Leucémie chronique lymphocytaire à cellules B</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antinéoplasiques</term><term>Inhibiteurs de protéines kinases</term><term>Pyrazoles</term><term>Pyrimidines</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Disease-Free Survival</term><term>Dose-Response Relationship, Drug</term><term>Female</term><term>Humans</term><term>Male</term><term>Mutation</term><term>Patient Compliance</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Femelle</term><term>Humains</term><term>Mutation</term><term>Mâle</term><term>Observance thérapeutique</term><term>Relation dose-effet des médicaments</term><term>Survie sans rechute</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><title>Key Points</title><p><list list-type="bullet"><list-item><p>Higher ibrutinib DI is associated with improved PFS, independent of del17p or <italic>TP53</italic> mutation.</p></list-item><list-item><p>Ibrutinib hold for >1 week, often needed to manage adverse events, is associated with increased PFS events.</p></list-item></list></p></div></front></TEI><affiliations><list><country><li>Australie</li><li>Autriche</li><li>Espagne</li><li>France</li><li>Italie</li><li>Pologne</li><li>Royaume-Uni</li><li>États-Unis</li></country><region><li>Angleterre</li><li>Californie</li><li>Catalogne</li><li>Grand Londres</li><li>Lombardie</li><li>Massachusetts</li><li>Ohio</li><li>Tennessee</li><li>Texas</li><li>Vienne (Autriche)</li><li>Washington (État)</li><li>État de New York</li><li>Île-de-France</li></region><settlement><li>Barcelone</li><li>Londres</li><li>Milan</li><li>Paris</li><li>Vienne (Autriche)</li></settlement></list><tree><country name="États-Unis"><region name="État de New York"><name sortKey="Barr, Paul M" sort="Barr, Paul M" uniqKey="Barr P" first="Paul M." last="Barr">Paul M. Barr</name></region><name sortKey="Barrientos, Jacqueline C" sort="Barrientos, Jacqueline C" uniqKey="Barrientos J" first="Jacqueline C." last="Barrientos">Jacqueline C. Barrientos</name><name sortKey="Brown, Jennifer R" sort="Brown, Jennifer R" uniqKey="Brown J" first="Jennifer R." last="Brown">Jennifer R. Brown</name><name sortKey="Burger, Jan A" sort="Burger, Jan A" uniqKey="Burger J" first="Jan A." last="Burger">Jan A. Burger</name><name sortKey="Byrd, John C" sort="Byrd, John C" uniqKey="Byrd J" first="John C." last="Byrd">John C. Byrd</name><name sortKey="Cole, George" sort="Cole, George" uniqKey="Cole G" first="George" last="Cole">George Cole</name><name sortKey="Coutre, Steven" sort="Coutre, Steven" uniqKey="Coutre S" first="Steven" last="Coutre">Steven Coutre</name><name sortKey="Furman, Richard R" sort="Furman, Richard R" uniqKey="Furman R" first="Richard R." last="Furman">Richard R. Furman</name><name sortKey="James, Danelle F" sort="James, Danelle F" uniqKey="James D" first="Danelle F." last="James">Danelle F. James</name><name sortKey="O Brien, Susan" sort="O Brien, Susan" uniqKey="O Brien S" first="Susan" last="O'Brien">Susan O'Brien</name><name sortKey="Pagel, John M" sort="Pagel, John M" uniqKey="Pagel J" first="John M." last="Pagel">John M. Pagel</name><name sortKey="Reddy, Nishitha M" sort="Reddy, Nishitha M" uniqKey="Reddy N" first="Nishitha M." last="Reddy">Nishitha M. Reddy</name><name sortKey="Sukbuntherng, Juthamas" sort="Sukbuntherng, Juthamas" uniqKey="Sukbuntherng J" first="Juthamas" last="Sukbuntherng">Juthamas Sukbuntherng</name><name sortKey="Suzuki, Samuel" sort="Suzuki, Samuel" uniqKey="Suzuki S" first="Samuel" last="Suzuki">Samuel Suzuki</name></country><country name="Royaume-Uni"><noRegion><name sortKey="Hillmen, Peter" sort="Hillmen, Peter" uniqKey="Hillmen P" first="Peter" last="Hillmen">Peter Hillmen</name></noRegion><name sortKey="Dearden, Claire" sort="Dearden, Claire" uniqKey="Dearden C" first="Claire" last="Dearden">Claire Dearden</name></country><country name="Australie"><noRegion><name sortKey="Mulligan, Stephen P" sort="Mulligan, Stephen P" uniqKey="Mulligan S" first="Stephen P." last="Mulligan">Stephen P. Mulligan</name></noRegion></country><country name="Autriche"><region name="Vienne (Autriche)"><name sortKey="Jaeger, Ulrich" sort="Jaeger, Ulrich" uniqKey="Jaeger U" first="Ulrich" last="Jaeger">Ulrich Jaeger</name></region></country><country name="France"><region name="Île-de-France"><name sortKey="Cymbalista, Florence" sort="Cymbalista, Florence" uniqKey="Cymbalista F" first="Florence" last="Cymbalista">Florence Cymbalista</name></region></country><country name="Italie"><region name="Lombardie"><name sortKey="Montillo, Marco" sort="Montillo, Marco" uniqKey="Montillo M" first="Marco" last="Montillo">Marco Montillo</name></region></country><country name="Pologne"><noRegion><name sortKey="Robak, Tadeusz" sort="Robak, Tadeusz" uniqKey="Robak T" first="Tadeusz" last="Robak">Tadeusz Robak</name></noRegion></country><country name="Espagne"><region name="Catalogne"><name sortKey="Moreno, Carol" sort="Moreno, Carol" uniqKey="Moreno C" first="Carol" last="Moreno">Carol Moreno</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A18 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000A18 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= PMC:5437732
|texte= Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:28373262" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |